FDA.reportPublic FDA data

alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast]

RxCUI
1233711
RxNorm name
alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast]
Display name
alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast]
Full name
alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:14

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125039Aralast, Aralast NpAlpha-1-Proteinase Inhibitor (Human)351(a)Rx2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
a9a5b46e-04da-41bd-bb5f-c4936b664fefAralast NP 1 MG Injection [PSN] · alpha 1-proteinase inhibitor, human 1 MG Injection [Aralast] [SBD] · Aralast 1 MG Injection [SY]320These highlights do not include all the information needed to use ARALAST NP safely and effectively. See full prescribing information for ARALAST NP. ARALAST ® NP (Alpha 1 -Proteinase Inhibitor (Human)) For Intravenous Use. Lyophilized Powder for Solution for Injection Initial U.S. Approval: 200220251125